“The underdiagnosis of haemophilia in India is alarming. Without proper screening facilities and awareness, many patients remain untreated, leading to severe complications,” Dr. Dikshit said. National ...

vector developed for the treatment of hemophilia B, led to sustained expression of the high-activity factor IX variant (FIX-R338L, or FIX-Padua) in a phase 1–2a study. The long-term safety and ...

She also underscored the contributions of the Hemophilia Association of the Philippines for Love and Service (HAPLOS), a support group of patients and advocates working to improve access to care and ...

STAT News Video - Video New CRISPR-based sickle cell treatment, explained Posted: April 15, 2025 | Last updated: April 15, 2025 The Food and Drug Administration has approved the world’s first ...

"We have a few other cases [globally] where the wrong embryo has been transferred resulting in the birth of a child." Ms Jefford said Australian families currently undertaking IVF treatment should ...

"I wish I was one of those people who knew what I needed to be doing all along, but I was probably using bar soap on my face ... that high-quality professional treatment. "The PCA peels are ...

Hemophilia A can be hereditary or, rarely, acquired later in life. Treatment for hemophilia A continues to evolve. Preventive treatment (prophylaxis) has relied on factor VIII products given through ...

“This approval represents important progress in the treatment of patients with hemophilia A in Canada,” Stephanie Veyrun-Manetti, general manager of specialty care and country lead at Sanofi Canada, ...

Her project focuses on developing fluorescent polymer nanoparticles to deliver CRISPR/Cas9 therapy, a cutting-edge DNA editing tool, for the treatment of dementia, including Alzheimer’s disease. With ...

The cost of the one-time hemophilia B gene therapy Hemgenix (etranacogene dezaparvovec) will now be covered for eligible patients in Germany through the country’s public healthcare system. This comes ...

Sanofi SNY and partner, Alnylam Pharmaceuticals ALNY, announced that the FDA has approved Qfitlia (fitusiran) as the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or ...